<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964869</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH110-REC2-055</org_study_id>
    <nct_id>NCT04964869</nct_id>
  </id_info>
  <brief_title>Efficacy of Prophylactic Epinephrine Solution Injection in Prevention of Delayed Post-sphincterotomy</brief_title>
  <official_title>Efficacy of Prophylactic Epinephrine Solution Injection in Prevention of Delayed Post-sphincterotomy Bleeding in Patients With Transient Bleeding During ERCP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wen-Hsin Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bleeding is the most frequently reported serious complication of endoscopic sphincterotomy,&#xD;
      and severe bleeding has occurred in about 1% to 2% of patients. Endoscopic injection of&#xD;
      epinephrine is the most commonly used, effective, and least expensive method for the&#xD;
      management of post- sphincterotomy bleeding. However, the efficacy of prophylactic&#xD;
      saline-epinephrine solution injection to prevent delayed EST bleeding when transient bleeding&#xD;
      During ERCP has not been established.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Backgroud:&#xD;
&#xD;
      Bleeding is the most frequently reported serious complication of endoscopic sphincterotomy,&#xD;
      and severe bleeding has occurred in about 1% to 2% of patients. Endoscopic injection of&#xD;
      epinephrine is the most commonly used, effective, and least expensive method for the&#xD;
      management of post- sphincterotomy bleeding. However, the efficacy of prophylactic&#xD;
      saline-epinephrine solution injection to prevent delayed EST bleeding when transient bleeding&#xD;
      During ERCP has not been established.&#xD;
&#xD;
      Study Rationale:&#xD;
&#xD;
      The hypotheses of the study is the prophylactic saline-epinephrine solution injection affects&#xD;
      incidence of delayed post-EST bleeding.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      A single blinded parallel group, multiple center, randomized controlled trial. The sample&#xD;
      size is estimated 400 (200 in injection group and 200 in non-injection group), The primary&#xD;
      outcome is the rate of delayed EST bleeding within 30 days of ERCP.&#xD;
&#xD;
      Study Objectives:&#xD;
&#xD;
      Primary objective: the rate of post-EST bleeding within 30 days of ERCP Secondary objectives:&#xD;
      the rate of post-ERCP advese effect, the increasing procedure time because of hemostasis, the&#xD;
      need for angiographic/endoscopic hemostasis times.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>post EST bleeding rate</measure>
    <time_frame>30 days</time_frame>
    <description>delay post-sphincterotomy bleeding rate</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Bleeding Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Epinephrine solution injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In injected group, The saline epinephrine solution (1mg in 10ml N/S) is injected to 2 sites of cutted papilla (1 o'clock and 11 o'clock) by injected needle, at least 0.5ml per injected site, and must be protruded from submucosal layer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-injection group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In non injection group, the saline epinephrine solution is not given</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>epinephrine solution injection</intervention_name>
    <description>epinephrine solution injection at least 1 ml to the post- sphincterotomy wound</description>
    <arm_group_label>Epinephrine solution injection group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 20 years or older.&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
          -  An naive major papilla.&#xD;
&#xD;
          -  Transient bleeding after endoscopic sphincterotomy&#xD;
&#xD;
          -  Bleeding less than 30 secs when end of procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior endoscopic sphincterotomy.&#xD;
&#xD;
          -  Thrombocytopenia (platelets &lt;50,000/mm3).&#xD;
&#xD;
          -  Liver cirrhosis (Child A-C)&#xD;
&#xD;
          -  CKD stage 4-5 and dialysis.&#xD;
&#xD;
          -  Allergy to epinephrine&#xD;
&#xD;
          -  Prolonged PT/APTT (INR&gt;1.5)&#xD;
&#xD;
          -  Had exposure any antithrombotic or antiplatelet agent in recent 7 days and/or will&#xD;
             take those agents in one month after EST&#xD;
&#xD;
          -  Ampulla Vater tumor&#xD;
&#xD;
          -  Active GI bleeding&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Limited visibility when immediate bleeding after sphincterotomy&#xD;
&#xD;
          -  Still bleeding after 30 secs when end of procedure&#xD;
&#xD;
          -  Recurrent bleeding during ERCP&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Hsin Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shih-Chieh Chuang, MD</last_name>
    <phone>+886-975680839</phone>
    <email>D18114@mail.cmuh.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen-Hsin Huang, MD</last_name>
    <phone>+886-4-2205-2121</phone>
    <phone_ext>2233</phone_ext>
    <email>u97766.huang@msa.hinet.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <state>North Dist.</state>
        <zip>404332</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Chieh Chuang, MD</last_name>
      <phone>+886-975680839</phone>
      <email>D18114@mail.cmuh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University Hospital</investigator_affiliation>
    <investigator_full_name>Wen-Hsin Huang</investigator_full_name>
    <investigator_title>Gastroenterology and Hepatology Deputy Director</investigator_title>
  </responsible_party>
  <keyword>sphincterotomy</keyword>
  <keyword>epinephrine solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

